162 related articles for article (PubMed ID: 9417443)
1. [Clinical significance of tumor suppressor gene p53 in head and neck tumors].
Preisler V; Kirchner S; Hagen R
HNO; 1997 Sep; 45(9):659-62. PubMed ID: 9417443
[No Abstract] [Full Text] [Related]
2. [Cell protein p53 in head-neck tumors].
Issing WJ
HNO; 1994 May; 42(5):249-50. PubMed ID: 8050909
[No Abstract] [Full Text] [Related]
3. [Significance of aberrant p53 protein in head-neck tumors and its effect on proliferation and differentiation].
Homann N; Andl T; Nees M; Schuhmann A; Herold-Mende C; Bosch FX
HNO; 1993 May; 41(5):254-60. PubMed ID: 8392993
[TBL] [Abstract][Full Text] [Related]
4. [Expression of tumor suppressor gene p53 and Rb in patients with epidermoid carcinoma of the head and neck].
Schipper JH; Kelker W
HNO; 1994 May; 42(5):270-4. PubMed ID: 8050915
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
[TBL] [Abstract][Full Text] [Related]
6. [Examinations on the importance of the inactivation of the tumor suppressor gene p16, reactivation of the telomerase and mutation of p53 in the pathogenesis of head and neck tumors].
Koscielny S
Laryngorhinootologie; 2003 Mar; 82(3):197-8. PubMed ID: 12673521
[No Abstract] [Full Text] [Related]
7. [The role of p53 tumor suppressor gene as prognostic factor in laryngeal squamous cell carcinoma].
Garozzo A; Cutrona D; Palmeri S; Maiolino L; Puzzo L; Allegra E
Acta Otorhinolaryngol Ital; 1999 Dec; 19(6):342-7. PubMed ID: 10875157
[TBL] [Abstract][Full Text] [Related]
8. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of p53-related proteins predicts rapid growth rate of head and neck cancer.
Edström S; Cvetkovska E; Westin T; Young C
Laryngoscope; 2001 Jan; 111(1):124-30. PubMed ID: 11192880
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of the diagnosis of p53 alterations in squamous cell carcinoma of the head and neck.
Lopez-Martinez M; Anzola M; Cuevas N; Aguirre JM; De-Pancorbo M
Med Oral; 2002; 7(2):108-20. PubMed ID: 11887018
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck.
Farhadieh RD; Smee R; Rees CG; Salardini A; Eggleton S; Yang JL; Russell PJ
ANZ J Surg; 2009; 79(1-2):48-54. PubMed ID: 19183379
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas.
Waitzberg AF; Nonogaki S; Nishimoto IN; Kowalski LP; Miguel RE; Brentani RR; Brentani MM
Cancer Detect Prev; 2004; 28(3):178-86. PubMed ID: 15225897
[TBL] [Abstract][Full Text] [Related]
13. The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck.
Akervall J; Bockmühl U; Petersen I; Yang K; Carey TE; Kurnit DM
Clin Cancer Res; 2003 May; 9(5):1750-5. PubMed ID: 12738730
[TBL] [Abstract][Full Text] [Related]
14. [p53 mutations and HPV infections in squamous epithelial carcinomas of the head-neck region. Long-term follow-up].
Riethdorf S; Friedrich RE; Sühwold J; Ostwald C; Barten M; Gogacz P; Gundlach KK; Schlechte H; Becker J; Bregenzer T; Riethdorf L; Löning T
Mund Kiefer Gesichtschir; 1998 Jan; 2(1):30-4. PubMed ID: 9522570
[TBL] [Abstract][Full Text] [Related]
15. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
[TBL] [Abstract][Full Text] [Related]
16. Clinical trails referral resource. Clinical trials of adenovirus-p53 gene therapy.
Zwiebel JA; Nagler C; Smiley JK; Cheson BD
Oncology (Williston Park); 1998 Aug; 12(8):1172, 1175. PubMed ID: 11236309
[No Abstract] [Full Text] [Related]
17. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases.
Ai L; Stephenson KK; Ling W; Zuo C; Mukunyadzi P; Suen JY; Hanna E; Fan CY
Mod Pathol; 2003 Sep; 16(9):944-50. PubMed ID: 13679459
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations in head and neck cancer.
Perrone F; Bossi P; Licitra L
N Engl J Med; 2008 Mar; 358(11):1194-5; author reply 1195. PubMed ID: 18340660
[No Abstract] [Full Text] [Related]
19. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas.
Rodrigo JP; García-Carracedo D; García LA; Menéndez S; Allonca E; González MV; Fresno MF; Suárez C; García-Pedrero JM
J Pathol; 2009 Mar; 217(4):516-23. PubMed ID: 18991334
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma.
Ferris RL; Grandis JR
Clin Cancer Res; 2007 Oct; 13(19):5663-4. PubMed ID: 17908953
[No Abstract] [Full Text] [Related]
[Next] [New Search]
